Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00715247|
Recruitment Status : Recruiting
First Posted : July 15, 2008
Last Update Posted : November 6, 2017
|Condition or disease|
|Polycythemia Vera Essential Thrombocythemia Myelofibrosis|
Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), also known as the Philadelphia Chromosome negative myeloproliferative disorders (MPDs), are not congenital, but acquired. The purpose of this project is to find genes whose mutations cause these disorders, as well as improve diagnostic measures for these diseases. When this is accomplished new therapies to control and eventually cure the disease can be designed.
All subjects will be asked to donate 4-6 teaspoons of blood. On occasion, if the blood cells from a particular sample do not grow well and the DNA from that sample is used up or other tests are needed, we may ask to collect additional samples. In patients who have undergone a bone marrow biopsy as part of their clinical evaluation, we will test the reproducibility between pathologists for the revised 2008 WHO diagnostic criteria to diagnose myeloproliferative disorders (MPD).
|Study Type :||Observational|
|Estimated Enrollment :||700 participants|
|Official Title:||Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes|
|Study Start Date :||July 2006|
|Estimated Primary Completion Date :||July 2020|
|Estimated Study Completion Date :||July 2020|
Patients suspected to have one of the following blood disorders: polycythemia vera, myelofibrosis or essential thrombocythemia.
Healthy Female Controls
Healthy females who do not have the blood disorders; Polycythemia Vera, Essential Thrombocythemia and/or Myelofibrosis.
- Identify genes whose mutations cause Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis. [ Time Frame: Weekly ]
- To determine if there are proteins expressed by cells from patients that might be targets for the immune response. [ Time Frame: Weekly ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00715247
|Contact: Josef T Prchal, MDfirstname.lastname@example.org|
|Contact: Kim Hickman, BSemail@example.com|
|United States, Utah|
|University of Utah||Recruiting|
|Salt Lake City, Utah, United States, 84132|
|Contact: Josef T Prchal, MD 801-581-4220 firstname.lastname@example.org|
|Contact: Kim Hickman, BS 801-581-3707 email@example.com|
|Sub-Investigator: Neeraj Agarwal, MD|
|Sub-Investigator: Mohamed Salama, MD|
|Sub-Investigator: Archana Agarwal, MD|
|Sub-Investigator: Todd Kelley, MD|
|Sub-Investigator: Maurizio Zangari, MD|
|Sub-Investigator: Michael Deininger, MD|
|Sub-Investigator: Sabina Swierczek, PhD|
|Principal Investigator:||Josef T Prchal, MD||University of Utah|